(S,R,S)-AHPC (TFA) is a high-affinity ligand specifically engineered for recruiting the Von Hippel-Lindau (VHL) E3 ubiquitin ligase, a critical component in the design of PROTAC (Proteolysis Targeting Chimera) molecules. Classified as a VHL E3 Ligase Ligand, this compound features a chemically optimized structure that enables efficient conjugation to target protein binders via a suitable linker. Through its selective binding to VHL, it facilitates ubiquitination and targeted degradation of disease-relevant proteins, making it an essential reagent in targeted protein degradation research and drug discovery. (S,R,S)-AHPC (TFA) is widely used in the development of next-generation therapeutics for oncology, neurodegeneration, and other areas involving undruggable targets.
Structure of 1631137-51-3
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
(S,R,S)-AHPC (TFA) is a potent and selective ligand for the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, widely used in the development of PROTACs (Proteolysis Targeting Chimeras). AHPC, or Aliphatic Hydroxyproline Carboxamide, is a hydroxyproline-based derivative optimized for strong VHL binding. The TFA (trifluoroacetate) salt form enhances its solubility and handling for chemical synthesis. This compound is a key building block in targeted protein degradation research, supporting the design and development of next-generation therapeutics.
Mechanism
(S,R,S)-AHPC binds specifically to the VHL E3 ligase component, thereby recruiting the VHL E3 ligase complex for ubiquitination of target proteins when integrated into PROTAC molecules. By conjugating (S,R,S)-AHPC to a ligand that recognizes a protein of interest, researchers create bifunctional molecules that direct the E3 ligase to tag the target protein for proteasomal degradation. The precise stereochemistry of the AHPC scaffold ensures optimal VHL engagement, resulting in efficient target ubiquitination and degradation.
Applications
(S,R,S)-AHPC (TFA) is broadly employed in the synthesis of VHL-based PROTACs, enabling selective degradation of disease-relevant proteins for both research and therapeutic applications. Its applications include:
• Construction of PROTAC molecules targeting various proteins for oncology, neurodegenerative diseases, and immunology
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.